Industry News
Pharmaceutical Industry News
This week on “The Top Line,” we…
This week on "The Top Line," we explore biopharma's rebound, dealmaking momentum and what's cutting through the noise in 2026.
AstraZeneca made a big commitment…
AstraZeneca made a big commitment to China as CEO Pascal Soriot joined British Prime Minister Keir Starmer on a trip to the country. Boehringer Ingelheim secured a preclinical inflammatory bowel disease bispecific from Simcere. Daiichi
On Wednesday, the U.S. Chamber of…
On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court decision that previously rejected Novo Nordisk's challenge of drug pricing provisions in the Inflation
The minute-long ad, which debuted…
The minute-long ad, which debuted online Thursday ahead of its broadcast premiere during the Feb. 8 game, starts with a stark claim: “Rich people live longer,” said by the ad’s narrator, the rapper and actor
A few months after sending an…
A few months after sending an untitled letter to ARS Pharmaceuticals, taking issue with certain aspects of a TV commercial about its epinephrine nasal spray, the FDA is reiterating its concerns about Neffy’s advertising language.
The gap between Vyvanse generic…
The gap between Vyvanse generic sales declines and growth from new products is narrowing, the Japanese company said on its third-quarter 2025 earnings call, which detailed financial performance from the nine months ending on Dec.
Amid mounting concerns about the…
Amid mounting concerns about the state of vaccine policy in the United States, Sanofi is keeping a cool head while acknowledging that sales of its immunizations are slated to dip slightly this year. The comments
Roche is looking to a busy 2026…
Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of closely watched breast cancer candidate giredestrant draws near. But behind another strong earnings
Bayer has unveiled the next play…
Bayer has unveiled the next play in its Nubeqa marketing strategy, tapping NFL quarterback-turned-CBS commentator Tony Romo for a campaign in support of its fast-growing prostate cancer drug.
Combining two eye drops that have…
Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval for Yuvezzi, a treatment for presbyopia, a common, age-related condition that makes
A year after debuting its first…
A year after debuting its first Super Bowl ad, Novartis is returning to advertising’s biggest stage on another awareness-raising mission, this time focusing on boosting prostate cancer screening.
Consumer advocacy organization…
Consumer advocacy organization Public Citizen has filed a Freedom of Information Act lawsuit against the Department of Health and Human Services and the Department of Commerce for failing to provide documents related to President Donald Trump’s
The pediatric medical group…
The pediatric medical group recommends children be vaccinated against 18 diseases, as opposed to the federal government's recent reduction to 11.
Shortly after acquiring Elektrofi…
Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.
With a third consecutive year of…
With a third consecutive year of sales growth under its belt, the company is expecting flat or slightly down revenues in 2026, it said.
Ro is bringing Serena Williams to…
Ro is bringing Serena Williams to the Super Bowl. Months after partnering with Williams, Ro has secured airtime at Super Bowl LX to showcase how the 23-time Grand Slam tennis champion’s life changed after taking
With Cellares preparing to begin…
With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.
Biosynthesis specialist Antheia…
Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia's total funding over the past year to more than
A new FDA nod for autologous stem…
A new FDA nod for autologous stem cell transplant-ineligible patients fortifies Darzalex Faspro's position for patients with newly diagnosed multiple myeloma.
Even as the Trump administration…
Even as the Trump administration works to implement its most-favored-nation pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.